| ●Editorial | Kuwata K | 657 | Full text | |
| ●Overcoming neurodegenerative diseases by innovative therapeutic developments －Toward the establishment of the clinical trial system for prion diseases－ Representative organizer：Kuwata K Organized by：Gifu University |
659-735 | Abstract | ||
| Opening remarks | Kuwata K | 661 | ||
| Strategy for prion disease control | Fukushima M | 662-72 | ||
| Temporal and regional variations in Japan and specific clinical signs
and/or symptoms as predictive factors of clinical course in sporadic Creutzfeldt-Jakob disease | Nakatani E | 673-9 | ||
| Development of clinical trial system in prion disease | Kuwata K | 680-7 | ||
| Surveillance and Japanese Consortium Of Prion disease (JACOP) for clinical researches | Mizusawa H | 688-94 | ||
| The investigator-initiated clinical trial organized by the Translational
Medical Center in the National Center of Neurology and Psychiatry | Takeda S | 695-700 | ||
| Neuroimaging in early-stage prion diseases | Sasaki M | 701-5 | ||
| Study for the early laboratory diagnosis of human prion diseases using CSF by the RT-QuIC assay | Nishida N | 706-11 | ||
| Immuno- and cell therapy as possible treatment for prion diseases | Horiuchi M | 712-8 | ||
| Pathogenic role of post-Golgi transport in prion disease | Sakaguchi S | 719-25 | ||
| Prion pathogenesis in animal models | Yokoyama T | 726-31 | ||
| Evaluation of the efficiency and safety of an anti-prion drug using the non-human primate model | Shibata H | 732 | ||
| Summary | Mohri S | 733-5 | ||
| ●4th World Centenarian Initiative 2nd Medical Technological Innovation Symposium in Hirosaki －Toward a society of zero bedridden & zero wheelchair－ Representative organizer：Ishibashi Y Organized by：Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine Hirosaki Memorial Hospital |
737-83 | Abstract | ||
| Opening remarks | Ishibashi Y | 739 | ||
| Cybernic neurorehabilitation using HAL medical model: Effect of cybernic walk treatment | Nakajima T | 740-6 | ||
| Development of robotic rehabilitation allowing disabled patients to walk independently | Takata S | 747-51 | ||
| Activities of Japan Spinal Cord Foundation, what patients think, and hope for developments of new therapies | Ohama M | 752-4 | ||
| Olfactory mucosa transplantation for spinal cord injury | Iwatsuki K | 755-9 | ||
| Cell therapy for spinal cord injury | Honmou O | 760-2 | ||
| Gait training with Hybrid Assistive Limb (HAL) for chronic incomplete spinal cord injury | Toda M | 763-6 | ||
| HAL clinical trial in Germany for patients with spinal cord injury | Schildhauer TA | 767 | ||
| Stroke care at Hirosaki Stroke and Rehabilitation Center | Iwata M | 768-72 | ||
| Rehabilitation with HAL | Asami T | 773-7 | ||
| Panel discussion | 778-9 | |||
| Future prospective of treatment for spinal cord injury and stroke | Fukushima M | 780-3 | ||
| ●Toward the global standardization of molecular imaging biomarkers | ||||
| Toward the global standardization of molecular imaging biomarkers: Activities of QIBA and its utilization for drug development | Kurihara C，Iizuka H， Inoue T | 785-91 | Abstract | |
| Objectives and current status of QIBA (Quantitative Imaging Biomarkers Alliance) | Sullivan DC （trans. by Iizuka H，Kurihara C， Inoue T） | 793-812 | Abstract | |
| ●Forum | ||||
| Report on the lecture on mycetoma, a serious infectious disease, given
by Dr. Ahmed Fahal, Professor of Surgery at the University of Khartoum, Sudan, who visited Japan in November 2016 －In 2016, mycetoma became the 18th disease to be added to WHO List of Neglected Tropical Diseases－ | DNDi Japan | 813-7 | ||
| ●Instructions for authors［Japanese］＆［English］ | 819-27 | Full text | ||
| ●Editor's note | Tsuchiya F | 829 | Full text | |
| ［Electronic publications only］ | ||||
| ●Invited lecture | ||||
| Objectives and current status of QIBA (Quantitative Imaging Biomarkers Alliance) | Sullivan DC | 831-52 W1-W22 | Full text | |